Last 12 months
Inside the activity.
1 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2022 Filed Mar 10, 2022 20:27 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock | 382,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000054 · wf-form4_164696201693474.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 940,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of the leveraged stock units granted to Mr. Williams on March 1, 2019, based on the cumulative performance of the Issuer's Class A Common Stock. F2 · balance_after: Includes restricted stock units granted under awards reported on Table I of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:28 UTC |
Shams AammaadController
|
Tax withholdingClass A Common Stock | 1,613 | $27.40 | $44,196.20 |
DisclosureSEC source: 0001628908-22-000037 · wf-form4_164636088317892.xml · nonDerivative · entry 2 Shams Aammaad · CIK 0001815354 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,637 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:28 UTC |
Shams AammaadController
|
GrantClass A Common Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000037 · wf-form4_164636088317892.xml · nonDerivative · entry 1 Shams Aammaad · CIK 0001815354 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 F1 · security: Represents restricted stock units granted to Mr. Shams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2023, and 33 % on March 1, 2024, and March 1, 2025. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:18 UTC |
Weinberg JonathanGeneral Counsel
|
Tax withholdingClass A Common Stock | 2,082 | $27.40 | $57,046.80 |
DisclosureSEC source: 0001628908-22-000031 · wf-form4_164636027342528.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,713 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:18 UTC |
Weinberg JonathanGeneral Counsel
|
GrantClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000031 · wf-form4_164636027342528.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,795 F1 · security: Represents restricted stock units granted to Mr. Weinberg pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2023, and 33 % on March 1, 2024, and March 1, 2025. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:34 UTC |
Johnson John PaulChief Financial Officer
|
Tax withholdingClass A Common Stock | 4,510 | $27.40 | $123,574.00 |
DisclosureSEC source: 0001628908-22-000039 · wf-form4_164636126999318.xml · nonDerivative · entry 2 Johnson John Paul · CIK 0001782040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,411 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:34 UTC |
Johnson John PaulChief Financial Officer
|
GrantClass A Common Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000039 · wf-form4_164636126999318.xml · nonDerivative · entry 1 Johnson John Paul · CIK 0001782040 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,921 F1 · security: Represents restricted stock units granted to Mr. Johnson pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2023, and 33 % on March 1, 2024, and March 1, 2025. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:25 UTC |
Blackley SethDirector · Chief Executive Officer
|
Tax withholdingClass A Common Stock | 5,285 | $27.40 | $144,809.00 |
DisclosureSEC source: 0001628908-22-000035 · wf-form4_164636073453327.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,548 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:25 UTC |
Blackley SethDirector · Chief Executive Officer
|
GrantClass A Common Stock | 64,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000035 · wf-form4_164636073453327.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,833 F1 · security: Represents restricted stock units granted to Mr. Blackley pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2023, and 33 % on March 1, 2024, and March 1, 2025. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:15 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 5,388 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001628908-22-000029 · wf-form4_164636012529223.xml · derivative · entry 5 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,388 Underlying: Class A Common Stock · 5,388 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F7 · derivative.exercise_date: The Class A Common Stock Options exercised vested on March 1, 2022. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:15 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 5,388 | $27.41 | $147,685.08 |
DisclosureSEC source: 0001628908-22-000029 · wf-form4_164636012529223.xml · nonDerivative · entry 4 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,838 F5 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.71 to $28.02, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:15 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 5,388 | $13.29 | $71,606.52 |
DisclosureSEC source: 0001628908-22-000029 · wf-form4_164636012529223.xml · nonDerivative · entry 3 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:15 UTC |
Tutewohl SteveChief Operating Officer
|
Tax withholdingClass A Common Stock | 4,005 | $27.40 | $109,737.00 |
DisclosureSEC source: 0001628908-22-000029 · wf-form4_164636012529223.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,838 F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:15 UTC |
Tutewohl SteveChief Operating Officer
|
GrantClass A Common Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-22-000029 · wf-form4_164636012529223.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,843 F1 · security: Represents restricted stock units granted to Mr. Tutewohl pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest at a rate of 34% on March 1, 2023, and 33 % on March 1, 2024, and March 1, 2025. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 17:07 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-22-000018 · wf-form4_164522204217116.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,060 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 17:07 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 10,000 | $23.70 | $237,000.00 |
DisclosureSEC source: 0001628908-22-000018 · wf-form4_164522204217116.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.39 to $24.27, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 17:07 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 10,000 | $23.70 | $237,000.00 |
DisclosureSEC source: 0001628908-22-000018 · wf-form4_164522204217116.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.39 to $24.27, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 17, 2022 Filed Feb 18, 2022 17:07 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-22-000018 · wf-form4_164522204217116.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 22:05 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 1,707 | $22.85 | $39,004.95 |
DisclosureSEC source: 0001628908-22-000009 · wf-form4_164427153879648.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,843 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.39 to $23.61, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 22:40 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 6,313 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-22-000007 · wf-form4_164375522107258.xml · derivative · entry 3 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,313 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 22:40 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 6,313 | $23.47 | $148,166.11 |
DisclosureSEC source: 0001628908-22-000007 · wf-form4_164375522107258.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,550 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.80, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 22:40 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 6,313 | $13.95 | $88,066.35 |
DisclosureSEC source: 0001628908-22-000007 · wf-form4_164375522107258.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:04 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-22-000005 · wf-form4_164271622660074.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 609,060 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:04 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 10,000 | $24.30 | $243,000.00 |
DisclosureSEC source: 0001628908-22-000005 · wf-form4_164271622660074.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 to $25.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:04 UTC |
WILLIAMS FRANK JDirector
|
SaleClass A Common Stock | 10,000 | $24.31 | $243,100.00 |
DisclosureSEC source: 0001628908-22-000005 · wf-form4_164271622660074.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 to $25.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 17:04 UTC |
WILLIAMS FRANK JDirector
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-22-000005 · wf-form4_164271622660074.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 17:56 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000154 · wf-form4_163978175839241.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 619,060 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 17:56 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $26.65 | $266,500.00 |
DisclosureSEC source: 0001628908-21-000154 · wf-form4_163978175839241.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.13 to $27.07, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 17:56 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $26.64 | $266,400.00 |
DisclosureSEC source: 0001628908-21-000154 · wf-form4_163978175839241.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.22 to $27.04, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 17:56 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-21-000154 · wf-form4_163978175839241.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 17:00 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000151 · wf-form4_163727281448722.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,060 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 17:00 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $27.81 | $278,100.00 |
DisclosureSEC source: 0001628908-21-000151 · wf-form4_163727281448722.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.42 to $28.07, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 17:00 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $27.81 | $278,100.00 |
DisclosureSEC source: 0001628908-21-000151 · wf-form4_163727281448722.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.45 to $28.09, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 17:00 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-21-000151 · wf-form4_163727281448722.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:01 UTC |
Sotunde TundeDirector
|
GrantClass A Common Stock | 3,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-21-000146 · wf-form4_163597330016463.xml · nonDerivative · entry 1 Sotunde Tunde · CIK 0001891237 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,405 F1 · security: Represents restricted stock units granted to Dr. Sotunde pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of November 1, 2022 and the date of the company's 2022 annual meeting, subject to the reporting person's continued service on the vesting date. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 16:14 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000137 · wf-form4_163476084489265.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,060 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 16:14 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $30.35 | $303,500.00 |
DisclosureSEC source: 0001628908-21-000137 · wf-form4_163476084489265.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.71 to $30.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 16:14 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $30.35 | $303,500.00 |
DisclosureSEC source: 0001628908-21-000137 · wf-form4_163476084489265.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.71 to $30.55, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| October 18, 2021 Filed Oct 20, 2021 16:14 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-21-000137 · wf-form4_163476084489265.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| October 15, 2021 Filed Oct 20, 2021 01:15 UTC |
Blackley SethDirector · Chief Executive Officer
|
Exercise / conversionClass A Common Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000135 · wf-form4_163469248900793.xml · derivative · entry 3 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,040 Underlying: Class A Common Stock · 150,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2015 and December 1, 2016. Read SEC document |
| October 15, 2021 Filed Oct 20, 2021 01:15 UTC |
Blackley SethDirector · Chief Executive Officer
|
SaleClass A Common Stock | 150,000 | $29.86 | $4,479,000.00 |
DisclosureSEC source: 0001628908-21-000135 · wf-form4_163469248900793.xml · nonDerivative · entry 2 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,842 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.66 to $30.07, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| October 15, 2021 Filed Oct 20, 2021 01:15 UTC |
Blackley SethDirector · Chief Executive Officer
|
Exercise / conversionClass A Common Stock | 150,000 | $3.84 | $576,000.00 |
DisclosureSEC source: 0001628908-21-000135 · wf-form4_163469248900793.xml · nonDerivative · entry 1 Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:34 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000128 · wf-form4_163312407962382.xml · derivative · entry 3 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 28,000 shares Expires 2024-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on November 1, 2015, November 1, 2016, November 1, 2017, and November 1, 2018. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:34 UTC |
Weinberg JonathanGeneral Counsel
|
SaleClass A Common Stock | 28,000 | $28.22 | $790,160.00 |
DisclosureSEC source: 0001628908-21-000128 · wf-form4_163312407962382.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.49, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:34 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock | 28,000 | $3.84 | $107,520.00 |
DisclosureSEC source: 0001628908-21-000128 · wf-form4_163312407962382.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 17:32 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000126 · wf-form4_163217352837587.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,060 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 17:32 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $26.27 | $262,700.00 |
DisclosureSEC source: 0001628908-21-000126 · wf-form4_163217352837587.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.02 to $26.51, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 17:32 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $26.27 | $262,700.00 |
DisclosureSEC source: 0001628908-21-000126 · wf-form4_163217352837587.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.47, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 17:32 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-21-000126 · wf-form4_163217352837587.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 21:19 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 13,553 | $25.05 | $339,502.65 |
DisclosureSEC source: 0001628908-21-000124 · wf-form4_163061757088336.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,550 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.16, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.